Skip to main content

Table 1 Quality assessment by the cochrane collaboration’s tool

From: Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis

Reference Random Sequence generation Allocation concealment Blinding of participants and personnel Blinding of outcome assessment Incomplete outcome data Selective reporting Other bias
Borghaei, H. [34] Unclear risk Unclear risk Unclear risk Low risk Low risk Unclear risk Unclear risk
Brahmer, J. [35] Unclear risk Unclear risk Unclear risk Unclear risk Low risk Unclear risk Unclear risk
Carbone, D. P. [36] Unclear risk Unclear risk Unclear risk Low risk Low risk Unclear risk Unclear risk
Hellmann, M. D. [33] Unclear risk Unclear risk Unclear risk Low risk Unclear risk Unclear risk Unclear risk
Wu, Y. L. [38] Low risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
Hellmann, M. D [39] Low risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
Bazhenova, L [40] Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk